64 reports of this reaction
3.8% of all NAFCILLIN SODIUM reports
#1 most reported adverse reaction
RENAL FAILURE ACUTE is the #1 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 64 FDA adverse event reports linking NAFCILLIN SODIUM to RENAL FAILURE ACUTE. This represents approximately 3.8% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience renal failure acute should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE ACUTE is moderately reported among NAFCILLIN SODIUM users, representing a notable but not dominant share of adverse events.
In addition to renal failure acute, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to renal failure acute in FDA adverse event reports:
RENAL FAILURE ACUTE has been reported as an adverse event in 64 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE ACUTE accounts for approximately 3.8% of all adverse event reports for NAFCILLIN SODIUM, making it one of the most commonly reported side effect.
If you experience renal failure acute while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.